Clinical Trial

Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer

Study acronym: JAZMINE
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The JAZMINE study is a multicenter, open-label, non-comparative, phase Ib/II clinical trial to evaluate safety and preliminary efficacy of zanidatamab in combination with tucatinib and chemotherapy (capecitabine or eribulin mesylate) in HER2-positive advanced breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-20.
Trial Details
NCT Number NCT07494448
Lead Sponsor MedSIR
Conditions HER 2 Positive Advanced Breast Cancer, Breast Cancer
Enrollment 24 participants
Start Date 2026-07-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-23